Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
-314
¥ millions (year-on-year change in consolidated operating profit)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Earnings presentationFirst quarter of the fiscal year ending March 20278 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥33,147 million+6.6%
Operating profit¥125 million-71.5%
Ordinary income¥84 million-79.1%
Net income¥-124 million profit attributable to owners of the parent
Operating profit margin0.4 %
Results for the three months of the current quarter
Net Sales
¥33,147 million
EBITDA
¥936 million
Operating profit
¥125 million
Ordinary income
¥84 million
Profit attributable to owners of parent for the quarter
¥-124 million
Full-year earnings forecast
Net Sales
¥136,000 million
EBITDA
¥6,420 million
Operating profit
¥3,000 million
Ordinary income
¥2,700 million
Profit attributable to owners of the parent
¥1,000 million
Earnings per share
¥34.21
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales24.4
EBITDA14.6
Operating profit4.2
Ordinary income3.1
Regional Pharmacy Network Business Revenue24.4
Regional Pharmacy Network Business Segment Profit14.2
Rental and Facilities-Related Business / Food-Service Business / Home-Visit Nursing Business Revenue22.3
Number of New Store Openings and M&A Transactions50
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
The number of new store openings and M&A transactions is expected to fall short of plan, while the attraction of medical institutions is expected to exceed planAssumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
The assumptions and factors cited include the impact of revisions to drug prices and medical service fees, as well as an increase in one-off systems investment; numerical assumptions are Not disclosedNew initiatives
- The non-login site of MEDISYS ONE, an integrated portal for pharmacies and medical institutions, will open ahead of schedule in July
- Organizing and standardizing service menus in the food, housing, sleep and prevention fields, and beginning their rollout at priority locations
- Establishing a cross-selling structure through the development and use of the customer management platform
- Launch of “Bilastine OD Tablets” in June 2026
- Strengthen alliances with manufacturing partners and expand the range of products handled
Key KPIsA metric the company considers important as a management benchmark.
- Number of support cases17,800 Facility
- Existing-store CCR¥238 millionYear-on-year (%)6.9
- ARPU¥96.1 thousandYear-on-year (%)16.7
- Number of trading locations9,517 LocationYear-on-year (%)23.6
- Number of products handled130 InstrumentYear-on-year (%)8.3
- Number of LINE official account friends for “つながる薬局” (Pharmacy Connect)200 10,000 peopleYear-on-year (%)45
Unit price and quantity metricsThese figures show sales broken down by price and volume.
- Existing-store prescription volume2,447 thousand prescriptionsYear-on-year (%)-0.5
- Existing-store prescription price per item¥10,852 per prescriptionYear-on-year (%)4.4
- Total-store prescription volume2,576 thousand prescriptionsYear-on-year (%)2.8
- Total-store prescription price per item¥10,701 per prescriptionYear-on-year (%)3.2
Segment results
- Community Pharmacy Network BusinessNet Sales¥32,183 millionRevenue_yoy_pct7.8Segment profit¥857 millionProfit_yoy_pct-19.5
- Rental and Facilities-Related Business / Food-Service Business / Home-Visit Nursing BusinessNet Sales¥1,162 millionRevenue_yoy_pct-17.9Segment profit¥-2 million
Number of stores and locations
Number of Stores at Period-End474 Location
New store openings during the period2 Location
Store Closures and Business Transfers During the Period1 Location
M&A During the Period1 Location
Capital expenditures
¥933 millions cash flow from investing activities
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥33,147 million (YoY +6.6%) |
| Operating profit | ¥125 million (YoY -71.5%) |
| Ordinary income | ¥84 million (YoY -79.1%) |
| Net income | ¥-124 million (profit attributable to owners of the parent) |
| Operating profit margin | 0.4 % |
| Results for the three months of the current quarter | Net Sales ¥33,147 million / EBITDA ¥936 million / Operating profit ¥125 million / Ordinary income ¥84 million / Profit attributable to owners of parent for the quarter ¥-124 million |
| Full-year earnings forecast | Net Sales ¥136,000 million / EBITDA ¥6,420 million / Operating profit ¥3,000 million / Ordinary income ¥2,700 million / Profit attributable to owners of the parent ¥1,000 million / Earnings per share ¥34.21 |
| Progress against full-year forecast | Net Sales 24.4 / EBITDA 14.6 / Operating profit 4.2 / Ordinary income 3.1 / Profit attributable to owners of the parent Not disclosed / Regional Pharmacy Network Business Revenue 24.4 / Regional Pharmacy Network Business Segment Profit 14.2 / Rental and Facilities-Related Business / Food-Service Business / Home-Visit Nursing Business Revenue 22.3 / Number of New Store Openings and M&A Transactions 50 |
| Self-assessment against the plan | The number of new store openings and M&A transactions is expected to fall short of plan, while the attraction of medical institutions is expected to exceed plan |
| Segment results | Segment Community Pharmacy Network Business / Net Sales ¥32,183 million / Revenue_yoy_pct 7.8 / Segment profit ¥857 million / Profit_yoy_pct -19.5, Segment Rental and Facilities-Related Business / Food-Service Business / Home-Visit Nursing Business / Net Sales ¥1,162 million / Revenue_yoy_pct -17.9 / Segment profit ¥-2 million / Profit_yoy_pct Not disclosed |
| Key KPIs | Indicator name Number of support cases / Value 17,800 Facility / Year on year against the same period last year Not disclosed, Indicator name Existing-store CCR / Value ¥238 million / Year-on-year (%) ¥6.9 million, Indicator name ARPU / Value ¥96.1 thousand / Year-on-year (%) ¥16.7 thousand, Indicator name Number of trading locations / Value 9,517 Location / Year-on-year (%) 23.6 Location, Indicator name Number of products handled / Value 130 Instrument / Year-on-year (%) 8.3 Instrument, Indicator name Number of LINE official account friends for “つながる薬局” (Pharmacy Connect) / Value 200 10,000 people / Year-on-year (%) 45 10,000 people |
| Unit price and quantity metrics | Indicator name Existing-store prescription volume / Value 2,447 thousand prescriptions / Year-on-year (%) -0.5 thousand prescriptions, Indicator name Existing-store prescription price per item / Value ¥10,852 per prescription / Year-on-year (%) ¥4.4 per prescription, Indicator name Total-store prescription volume / Value 2,576 thousand prescriptions / Year-on-year (%) 2.8 thousand prescriptions, Indicator name Total-store prescription price per item / Value ¥10,701 per prescription / Year-on-year (%) ¥3.2 per prescription |
| Number of stores and locations | Number of Stores at Period-End 474 Location / New store openings during the period 2 Location / Store Closures and Business Transfers During the Period 1 Location / M&A During the Period 1 Location |
| Assumptions Underlying the Business Outlook | The assumptions and factors cited include the impact of revisions to drug prices and medical service fees, as well as an increase in one-off systems investment; numerical assumptions are Not disclosed |
| Capital expenditures | ¥933 millions (cash flow from investing activities) |
| New initiatives | The non-login site of MEDISYS ONE, an integrated portal for pharmacies and medical institutions, will open ahead of schedule in July, Organizing and standardizing service menus in the food, housing, sleep and prevention fields, and beginning their rollout at priority locations, Establishing a cross-selling structure through the development and use of the customer management platform, Launch of “Bilastine OD Tablets” in June 2026, Strengthen alliances with manufacturing partners and expand the range of products handled |
Items this document does not state (13)
Gross Profit MarginSelling, general and administrative expensesBreakdown of Factors Affecting the ChangeNumber of employeesRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that revenue increased but profit declined because, despite the steady expansion of supported facilities, personnel costs rose and systems-related costs increased in connection with integrating the customer management platform and improving existing systems. It also cited a decline in the number of patients with acute diseases as the infectious disease outbreak subsided, as well as the transfer of part of its contracted food-service business.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.